USD 490 million, it ranks among the largest transactions in the Dutch biotech sector in recent years. Through the acquisition, BioMarin obtains Alesta’s lead clinical-stage asset, ALE 1, adding an important clinical program to its pipeline.
ALE1 is an orally active, small molecule for the potential treatment of hypophosphatasia (HPP), a rare genetic bone disease that can affect bone and tooth mineralisation, resulting in easy or frequent bone breaks, early tooth loss, and, in adults, clinically significant muscle weakness, fatigue and pain. ALE1 has the potential to be the first oral therapy for HPP and is currently being evaluated in an ongoing clinical trial assessing.
As part of the transaction, all non-ALE 1 assets of Alesta will be spun out into a newly established entity, with Alesta’s employees transferring to the spinout entity prior to closing. Our firm will continue to advise the new spinout entity.
Our team advising on the transaction further included Ruben Rekers, Joost Kloosterman, Emma Wiggers, Auke Knigge, and Jorn Riemersma, (Corporate M&A), Sophie van Lanschot, Daan Hagelstein, Josephine de Graaf, Daphne Smiggels (Corporate Notarial), Nico Blom, Riemer Meinderts (Tax), Daniël Kuiper, Sophie Schouten, Inger van Dijkman (Employment), Liselotte Bekke, Laura van Weeren (IP), and Danique Knibbeler (Data Protection).
Press coverage:
- FD: Nederlands biotechbedrijf Alesta sluit deal van $275 mln
- BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline | BioMarin
- BioMarin to acquire Alesta Therapeutics for $275 million
- BioMarin spends up to $490m for Alesta’s bone disease candidate - Pharmaceutical Technology
